Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naive HIV-1 infected patients-24-month results from the German TAFNES cohort stud-MedSci.cn

Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naive HIV-1 infected patients-24-month results from the German TAFNES cohort stud

Pauli, R; Jessen, H; Postel, N; Heuchel, T; Rieke, A; Hillenbrand, H; Kuemmerle, T; Schreiber, S; Goerner, K; Heinzkill, M; Haubrich, R; Stellbrink, HJ

HIV MEDICINE, 2019; 20 (): 54

科室
- - 订阅+
  - 更多科室
工具
服务